Inibace Plus

Cilazapril/Hydrochlorothiazide, the active ingredients in Inibace Plus, constitute an ACE inhibitor combined with a thiazide diuretic presented as a tablet for oral use. This combination therapy is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure and reduce cardiovascular risk.

GNH USA supplies Inibace Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets across multiple continents.

Inibace Plus, containing cilazapril and hydrochlorothiazide, is used in the management of hypertension, a condition characterized by elevated arterial pressure.

Hypertension: lowers elevated blood pressure and helps reduce the risk of cardiovascular events.

Common Side Effects: - Dizziness or light‑headedness - Persistent dry cough - Headache - Increased urination or electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Severe hypotension or syncope - Angioedema involving face, lips, tongue, or airway - Acute renal impairment or rise in serum creatinine - Hyperuricemia or gout flare - Pancreatitis or severe skin reactions

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolyte balance: monitor potassium and sodium levels due to thiazide effect. - Pregnancy: contraindicated in pregnancy (Category D) because of fetal risk. - Elderly patients: start at lower doses and watch for orthostatic hypotension. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Inibace Plus may interact with several medicines that affect blood pressure, renal function, or electrolyte balance.

Major Interactions (Avoid): - Co‑administration with other ACE inhibitors, ARBs, or aliskiren in diabetic patients can cause severe renal dysfunction. - Concurrent use of potassium‑sparing diuretics or supplements may lead to hyperkalaemia. - NSAIDs (e.g., ibuprofen, naproxen) can diminish antihypertensive efficacy and worsen renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, calcium channel blockers) may increase the risk of hypotension; dose adjustments may be needed. - Lithium therapy can have increased serum lithium levels, requiring close monitoring.